TapImmune Inc. (TPIV) Is Pleased To Announce The Signing Of An Exclusive Option Agreement For A New Phase 1 Clinical Program In Breast And Ovarian Cancer
3/19/2014 9:02:38 AM
SEATTLE--(BUSINESS WIRE)--TapImmune Inc. (OTCQB: TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by